CN102548551A - 治疗hiv感染的n-羟基-苯甲酰胺衍生物 - Google Patents

治疗hiv感染的n-羟基-苯甲酰胺衍生物 Download PDF

Info

Publication number
CN102548551A
CN102548551A CN2010800454818A CN201080045481A CN102548551A CN 102548551 A CN102548551 A CN 102548551A CN 2010800454818 A CN2010800454818 A CN 2010800454818A CN 201080045481 A CN201080045481 A CN 201080045481A CN 102548551 A CN102548551 A CN 102548551A
Authority
CN
China
Prior art keywords
compound according
inhibitors
alkyl
mono
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800454818A
Other languages
English (en)
Chinese (zh)
Inventor
C·迪纳雷洛
G·波萨蒂
P·马斯卡尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SpA
Original Assignee
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SpA filed Critical Italfarmaco SpA
Publication of CN102548551A publication Critical patent/CN102548551A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800454818A 2009-10-23 2010-09-14 治疗hiv感染的n-羟基-苯甲酰胺衍生物 Pending CN102548551A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2009A001837A IT1396915B1 (it) 2009-10-23 2009-10-23 Dietil-[6-(4-idrossicarbamoil-fenil-carbamoilossimetil)-naftalen-2-il-metil]-ammonio cloruro ed altri derivati della n-idrossi-benzammide per l'uso nel trattamento di infezioni da hiv.
ITMI2009A001837 2009-10-23
PCT/IB2010/054139 WO2011048514A1 (en) 2009-10-23 2010-09-14 Derivatives of n-hydroxybenzamide for treating hiv infections

Publications (1)

Publication Number Publication Date
CN102548551A true CN102548551A (zh) 2012-07-04

Family

ID=42153811

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800454818A Pending CN102548551A (zh) 2009-10-23 2010-09-14 治疗hiv感染的n-羟基-苯甲酰胺衍生物

Country Status (10)

Country Link
US (1) US8637702B2 (https=)
EP (1) EP2490682A1 (https=)
JP (1) JP5746196B2 (https=)
KR (1) KR101687644B1 (https=)
CN (1) CN102548551A (https=)
BR (1) BR112012008780A2 (https=)
CA (1) CA2773210C (https=)
IN (1) IN2012DN03387A (https=)
IT (1) IT1396915B1 (https=)
WO (1) WO2011048514A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022088047A1 (zh) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Itf2357在制备预防和治疗冠状病毒的药物中的应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6272773B2 (ja) * 2011-11-29 2018-01-31 ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． Ｈｄａｃ６阻害剤・抗腫瘍剤用複素環アミド化合物
CN107007580A (zh) 2012-02-03 2017-08-04 意大发马克股份公司 用于治疗肌肉萎缩症的化合物
IT201600074606A1 (it) * 2016-07-18 2018-01-18 Italfarmaco Spa New benzo-N-hydroxy amide compounds having antitumor activity
US11149082B2 (en) 2016-10-17 2021-10-19 University Of Maryland, College Park Multispecific antibodies targeting human immunodeficiency virus and methods of using the same
IT201900003281A1 (it) * 2019-03-06 2020-09-06 Chemi Spa Processo per preparare {6-[(dietilammino)metil]naftalen-2-il}metil [4-(idrossicarbamoil)fenil]carbammato ad elevata purezza

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960631A (zh) * 2004-03-18 2007-05-09 萨马利坦制药有限公司 苯甲酰胺和苯甲酸酯抗hiv化合物
CN1980886A (zh) * 2004-07-05 2007-06-13 意大利法尔马科有限公司 具有抗炎活性的α－氨基酸衍生物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1283637B1 (it) 1996-05-14 1998-04-23 Italfarmaco Spa Composti ad attivita' antinfiammatoria ed immunosoppressiva
ITMI20030025A1 (it) 2003-01-10 2004-07-11 Italfarmaco Spa Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
ITMI20030063A1 (it) 2003-01-17 2004-07-18 Italfarmaco Spa Cloridrato monoidrato dell'estere (6-dietilamminometil-naftalen-2-il)metilico dell'acido (4-idrossicarbammoil-fenil)carbammico.
US20100324034A1 (en) 2007-02-08 2010-12-23 Hazuda Daria J Methods of Using SAHA for Treating HIV Infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1960631A (zh) * 2004-03-18 2007-05-09 萨马利坦制药有限公司 苯甲酰胺和苯甲酸酯抗hiv化合物
CN1980886A (zh) * 2004-07-05 2007-06-13 意大利法尔马科有限公司 具有抗炎活性的α－氨基酸衍生物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
《Applied Microbiology and Biotechnology》 20071231 Daniel Riester et al. Histone deacetylase inhibitors-turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases 第499-514页 1-10 第75卷, 第7期 *
A. WANCHU ET AL.: "Pentoxiphylline reduces nitric oxide production among patients with HIV infection", 《IMMUNOLOGY LETTERS》 *
ANDREA SAVARINO ET AL.: ""Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence", 《RETROVIROLOGY》 *
DANIEL RIESTER ET AL.: "Histone deacetylase inhibitors—turning epigenic mechanisms of gene regulation into tools of therapeutic intervention in malignant and other diseases", 《APPLIED MICROBIOLOGY AND BIOTECHNOLOGY》 *
LEONARD C. EDELSTEIN ET AL.: "Short Communication: Activation of Latent HIV Type 1 Gene Expression by Suberoylanilide Hydroxamic Acid (SAHA), an HDAC Inhibitor Approved for Use to Treat Cutaneous T Cell Lymphoma", 《AIDS RESEARCH AND HUMAN RETROVIRUSES》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022088047A1 (zh) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Itf2357在制备预防和治疗冠状病毒的药物中的应用

Also Published As

Publication number Publication date
ITMI20091837A1 (it) 2011-04-23
KR20120083356A (ko) 2012-07-25
IT1396915B1 (it) 2012-12-20
KR101687644B1 (ko) 2016-12-19
US8637702B2 (en) 2014-01-28
JP2013508349A (ja) 2013-03-07
JP5746196B2 (ja) 2015-07-08
IN2012DN03387A (https=) 2015-10-23
CA2773210C (en) 2017-01-03
US20120203014A1 (en) 2012-08-09
WO2011048514A1 (en) 2011-04-28
CA2773210A1 (en) 2011-04-28
BR112012008780A2 (pt) 2020-12-01
EP2490682A1 (en) 2012-08-29

Similar Documents

Publication Publication Date Title
US12083119B2 (en) Methods and compositions for treating viral or virally-induced conditions
US8247613B2 (en) Methods and compositions for the synergistic activation of latent HIV
JP2022058416A (ja) ヘルペスウイルス誘発疾患の処置のための方法および組成物
US20150133434A1 (en) Compositions and Methods for Reactivating Latent Immunodeficiency Virus
US20060009527A1 (en) Method of treating TRX mediated diseases
Khan et al. Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins
CN102548551A (zh) 治疗hiv感染的n-羟基-苯甲酰胺衍生物
CN111743899B (zh) 硝唑尼特及其活性形式替唑尼特在制备用于治疗SARS-CoV-2感染的药物中的应用
US20230087766A1 (en) Methods of reactivating latent human immunodeficiency virus and related compositions
US20240058347A1 (en) Dosages for hdac treatment with reduced side effects
US10953011B2 (en) Methods of treating virally associated cancers with histone deacetylase inhibitors
TW202110452A (zh) 以組蛋白去乙醯酶抑制劑治療病毒相關癌症之方法
RU2009120115A (ru) Фармацевтическая композиция, обладающая антипсихотической, антидепрессантной или противоэпилептической активностью, со сниженным побочным эффектом
JP2023534723A (ja) コロナウイルス感染症の治療におけるベンフルメトール及びその誘導体の応用
Szaniawski et al. Senotherapeutics and HIV-1 persistence
Graci et al. Identification of benzazole compounds that induce HIV-1 transcription
RU2819782C2 (ru) Способы лечения ассоциированных с вирусом форм рака с помощью ингибиторов гистондеацетилазы
HK40033228A (en) Application of nitazoxanide and its active form tizoxanide in manufacture of a medicament for treating sars-cov-2 infection

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20120704

RJ01 Rejection of invention patent application after publication